Allogene Therapeutics
Quentin Smith is a skilled biotechnology professional with experience in various scientific roles. Currently serving as a Senior Associate Scientist at Allogene Therapeutics since February 2022, Quentin previously held the position of Associate Scientist. Prior experience includes working at Kit from August 2019 to February 2021 as a Laboratory Technician and Inventory Manager, where responsibilities involved running lab samples and managing inventory logistics. Earlier, Quentin worked at UPS as a Package Handler from August 2014 to December 2018, ensuring efficient and safe package transportation. Educational qualifications include a Master's degree in Biotechnology from the University of San Francisco (2019-2021), a Bachelor's degree in Biology from California State Polytechnic University-Pomona (2013-2016), and an Associate’s degree in Biology from Chaffey College (2009-2013).
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.